Sogand Vahidi

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 8

Top Topics

Squamous Cell Carcinoma

Top Venues

European journal of microbiology & immunology

Medical oncology (Northwood, London, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Arefeh Zabeti Touchaei, Sogand Vahidi, Ali Akbar Samadani
Immune landscape in APC and TP53 related tumor microenvironment in colon adenocarcinoma: A bioinformatic analysis. European journal of microbiology & immunology (2024)
Arefeh Zabeti Touchaei, Sogand Vahidi, Ali Akbar Samadani
Immune landscape in APC and TP53 related tumor microenvironment in colon adenocarcinoma: A bioinformatic analysis. European journal of microbiology & immunology 14 (2) (2024)
Arefeh Zabeti Touchaei, Sogand Vahidi, Ali Akbar Samadani
Immune landscape in APC and TP53 related tumor microenvironment in colon adenocarcinoma: A bioinformatic analysis. European journal of microbiology & immunology 14 (2) (2024)
Arefeh Zabeti Touchaei, Sogand Vahidi, Ali Akbar Samadani
Immune landscape in APC and TP53 related tumor microenvironment in colon adenocarcinoma: A bioinformatic analysis. European journal of microbiology & immunology 14 (2) (2024)
Arefeh Zabeti Touchaei, Sogand Vahidi, Ali Akbar Samadani
Immune landscape in APC and TP53 related tumor microenvironment in colon adenocarcinoma: A bioinformatic analysis. European journal of microbiology & immunology 14 (2) (2024)
Arefeh Zabeti Touchaei, Sogand Vahidi, Ali Akbar Samadani
Decoding the interaction between miR-19a and CBX7 focusing on the implications for tumor suppression in cancer therapy. Medical oncology (Northwood, London, England) 41 (1) (2023)
Arefeh Zabeti Touchaei, Sogand Vahidi, Ali Akbar Samadani
Decoding the interaction between miR-19a and CBX7 focusing on the implications for tumor suppression in cancer therapy. Medical oncology (Northwood, London, England) 41 (1) (2023)
Arefeh Zabeti Touchaei, Sogand Vahidi, Ali Akbar Samadani
Decoding the interaction between miR-19a and CBX7 focusing on the implications for tumor suppression in cancer therapy. Medical oncology (Northwood, London, England) 41 (1) (2023)